Trial Profile

A Randomized, Phase 2, Study to Assess the Safety and Activity of CRLX101, a Nanoparticle Formulation of Camptothecin, in Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed One or Two Previous Regimens of Chemotherapy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 30 May 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camptothecin (Primary)
Indications Adenocarcinoma; Large cell carcinoma; Non-small cell lung cancer; Squamous cell cancer
Focus Therapeutic Use
Sponsors Cerulean Pharma

03 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
10 Jul 2014 Planned End Date changed from 1 Feb 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.
20 Sep 2013 Planned End Date changed from 1 Apr 2014 to 1 Feb 2014 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com